Biodistribution and scintigraphic studies of 153Sm-labeled anti-CEA monoclonal antibody for radioimmunoscintigraphy and radioimmunotherapy

Fani, M; Xanthopoulos, S; Archimandritis, SC; Stratis, N; Bouziotis, P; Loudos, G; Varvarigou, AD

dc.contributor.author	Fani, M	en
dc.contributor.author	Xanthopoulos, S	en
dc.contributor.author	Archimandritis, SC	en
dc.contributor.author	Stratis, N	en
dc.contributor.author	Bouziotis, P	en
dc.contributor.author	Loudos, G	en
dc.contributor.author	Varvarigou, AD	en
dc.date.accessioned	2014-03-01T02:42:12Z
dc.date.available	2014-03-01T02:42:12Z
dc.date.issued	2003	en
dc.identifier.issn	0250-7005	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/30862
dc.relation.uri	http://www.scopus.com/inward/record.url?eid=2-s2.0-0042807278&partnerID=40&md5=d477763e9ad0afdaec456ba086d59c63	en
dc.subject	Anti-CEA monoclonal antibody	en
dc.subject	Radioimmunoscintigraphy	en
dc.subject	Radioimmunotherapy	en
dc.subject	Samarium-153	en
dc.subject.classification	Oncology	en
dc.subject.other	acid anhydride	en
dc.subject.other	carcinoembryonic antibody	en
dc.subject.other	chelating agent	en
dc.subject.other	monoclonal antibody	en
dc.subject.other	pentetic acid	en
dc.subject.other	samarium 153	en
dc.subject.other	animal experiment	en
dc.subject.other	animal model	en
dc.subject.other	animal tissue	en
dc.subject.other	antibody labeling	en
dc.subject.other	antibody specificity	en
dc.subject.other	antigen antibody reaction	en
dc.subject.other	antigen expression	en
dc.subject.other	bioaccumulation	en
dc.subject.other	colon cancer	en
dc.subject.other	conference paper	en
dc.subject.other	controlled study	en
dc.subject.other	diagnostic imaging	en
dc.subject.other	drug clearance	en
dc.subject.other	drug distribution	en
dc.subject.other	drug targeting	en
dc.subject.other	drug uptake	en
dc.subject.other	evaluation	en
dc.subject.other	female	en
dc.subject.other	gamma radiation	en
dc.subject.other	human	en
dc.subject.other	human cell	en
dc.subject.other	immunoscintigraphy	en
dc.subject.other	isotope labeling	en
dc.subject.other	kidney	en
dc.subject.other	liver	en
dc.subject.other	lung	en
dc.subject.other	mouse	en
dc.subject.other	nonhuman	en
dc.subject.other	nude mouse	en
dc.subject.other	parameter	en
dc.subject.other	plasma clearance	en
dc.subject.other	priority journal	en
dc.subject.other	radioactivity	en
dc.subject.other	radioimmunotherapy	en
dc.subject.other	reticuloendothelial system	en
dc.subject.other	scintillation camera	en
dc.subject.other	tissue distribution	en
dc.subject.other	tumor volume	en
dc.subject.other	Animals	en
dc.subject.other	Antibodies, Monoclonal	en
dc.subject.other	Carcinoembryonic Antigen	en
dc.subject.other	Female	en
dc.subject.other	Immunoconjugates	en
dc.subject.other	Mice	en
dc.subject.other	Mice, Nude	en
dc.subject.other	Radioimmunotherapy	en
dc.subject.other	Radioisotopes	en
dc.subject.other	Radiopharmaceuticals	en
dc.subject.other	Samarium	en
dc.subject.other	Tissue Distribution	en
dc.title	Biodistribution and scintigraphic studies of 153Sm-labeled anti-CEA monoclonal antibody for radioimmunoscintigraphy and radioimmunotherapy	en
heal.type	conferenceItem	en
heal.language	English	en
heal.publicationDate	2003	en
heal.abstract	The anti-CEA monoclonal antibody, which selectively localizes in colon cancer, was labeled with Samaritan-153 (Sm-153). Sm-153 is mainly a beta-emitter which can be used for therapeutic purposes, while its gamma-ray facilitates imaging studies. Labeling was achieved using the bicyclic anhydride of DTPA as chelator for Sm-153 tagging onto the antibody. [153Sm]anti-CEA was biologically evaluated in nude mice bearing tumors of different weight (0.5-2.5g), at diverse time intervals (4-72 hours), by anatomic and imaging methods. Biodistribution studies showed slow blood clearance and high retention in the liver, kidneys and lungs. In nude mice bearing tumors of about the same weight. uptake increased with time, from 4 to 72 hours post injection (p.i.). Highest uptake was observed in 0.5-0.8g tumors compared to those of 1.5-2.5g. The results agreed with imaging studies performed on a gamma camera at 4 to 72 hours p.i. Tumor uptake depended on time and tumor weight. The tumor can be visualized 24 hours p.i. but, due to the high background, it can be clearly distinguished at 72 hours p.i.	en
heal.publisher	INT INST ANTICANCER RESEARCH	en
heal.journalName	Anticancer Research	en
dc.identifier.isi	ISI:000184359100028	en
dc.identifier.volume	23	en
dc.identifier.issue	3 A	en
dc.identifier.spage	2195	en
dc.identifier.epage	2199	en